Brind.

UniQure is advancing its ALS programs, including AMT-130 targeting Huntington’s disease, with FDA alignment supporting BLA submission.

2 reports, 1 independent Updated Jul 29

Gone quiet

Reports: 2
Developments: 2
Repetition: 0%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

UniQure is advancing its ALS programs, including AMT-130 targeting Huntington’s disease, with FDA alignment supporting BLA submission.

Who's involved

What this event is mainly about

UniQure (Netherlands)FDA Als

How it developed

Newest first. Tap a step to see who reported it.

Jul 29UniQure advances ALS programs and AMT-130 for Huntington's disease, receiving FDA alignment.1 source
- GlobeNewswire
Jul 22UniQure achieved historic approval for gene therapies for Huntington's and ALS.1 source
- GlobeNewswire

Keep exploring

The entities involved

UniQure (Netherlands)
company in Amsterdam, Netherlands
- Trump pledged to unleash American oil and gas and advised investors on market timing in August 2025.Sun 04:14
FDA
- Generic medicine services are seeking approval for launch from the FDA.Mon 17:49
- A company is seeking FDA feedback on its NEO212 program, with a meeting scheduled at the FDA's White Oak campus.Mon 14:56
Als
river in Vienna

Nothing else this week.

Coverage

Newest first; wire copies grouped

Jul 29GlobeNewswireuniQure Announces Second Quarter 2025 Financial Results and Highlights of Recent Company Progress ~ Achieved alignment with the FDA on the AMT-130 statistical analysis plan and CMC requirements to su
Jul 22GlobeNewswireuniQure to Announce Second Quarter 2025 Financial Results uniQure to host earnings call on Tuesday, July 29, 2025 at 8:30 a.m. ET LEXINGTON, Mass. and AMSTERDAM, July 22, 2025 (GLOBE NEWSWIRE) -- uni